drugset / Trial / NCT02250482

An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

NCT02250482

Phase 3 Completed Bio Products Laboratory
Treatment

Summary

The main objective of the study is to investigate the safety and efficacy of Optivate®, administered in appropriate dosage to present bleeding and achieve haemostasis in patients with Haemophilia A undergoing surgery.

Timeline

Start
2001-11
Primary completion
2003-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Wilate Protein / enzyme biologic

Indications